Core Insights - Cartesian Therapeutics is advancing its mRNA cell therapy pipeline, particularly focusing on Descartes-08 for myasthenia gravis and systemic lupus erythematosus [1][2][3] Descartes-08 Updates - The Phase 3 AURORA trial for Descartes-08 in myasthenia gravis is set to begin in the first half of 2025, following positive Phase 2b results showing an average MG Activities of Daily Living (MG-ADL) reduction of 5.5 at Month 4 [1][3] - Descartes-08 has demonstrated a favorable safety profile, allowing for outpatient administration without preconditioning chemotherapy [2][3] - The ongoing Phase 2 trial for systemic lupus erythematosus is expected to provide data readout in the second half of 2025, with the disease affecting approximately 1.5 million people in the U.S. [3] Future Trials and Designations - A Phase 2 basket trial for Descartes-08 in pediatric patients with select autoimmune diseases is anticipated to start later in 2025, with Rare Pediatric Disease Designation already granted for juvenile dermatomyositis [3][5] - Descartes-08 has received Orphan Drug Designation and Regenerative Medicine Advanced Therapy Designation from the FDA for treating myasthenia gravis [5] Descartes-15 Development - The first-in-human Phase 1 clinical trial for Descartes-15, an autologous anti-BCMA mRNA CAR-T cell therapy, is currently underway, focusing on safety and tolerability in multiple myeloma patients [4][6] - Descartes-15 has shown a ten-fold increase in CAR expression in preclinical studies compared to Descartes-08, maintaining the outpatient administration advantage [6] Company Overview - Cartesian Therapeutics is a clinical-stage biotechnology company specializing in mRNA cell therapy for autoimmune diseases, with a pipeline that includes both Descartes-08 and Descartes-15 [7]
Cartesian Therapeutics Highlights Progress and 2025 Strategic Priorities Across Pipeline of mRNA Cell Therapies for Autoimmune Diseases